Last update Jan. 21, 2014

Aprepitant

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

On latest update relevant data on breastfeeding was not found.

Its moderately high molecular weight, and, especially a high plasma protein binding make excretion into breast milk unlikely

Side effects are few and usually mild.

Alternatives

  • Domperidone ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoclopramide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ondansetron ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Group

Aprepitant belongs to this group or family:

Tradenames

Main tradenames from several countries containing Aprepitant in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 59 - 67 %
Molecular weight 543 daltons
Protein Binding 97 %
VD 1 l/Kg
Tmax 3 - 4 hours
T½ 9 - 13 hours

References

  1. Merck Sharp & Dohme (NZ) Ltd Aprepitant Data Sheet 2009 Full text (in our servers)
  2. EMEA Aprepitant Ficha técnica 2008 Full text (in our servers)
  3. Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K, Knops A, De Lepeleire I, Michiels N, Petty KJ. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006 Abstract
  4. Patel L, Lindley C. Aprepitant--a novel NK1-receptor antagonist. Expert Opin Pharmacother. 2003 Abstract

Total visits

2,877

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM